Lots of strange approvals in Japan that neglect trial data.
www.science.org/content/arti...
science.org
In a ‘shocker’ decision, Japan approves mpox drug that failed in two efficacy trials
Earlier European authorizations for tecovirimat are also being scrutinized in the face of fresh data